Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLB101 vs Blincyto in adults with relapsed or refractory CD19-positive precursor B-cell acute lymphoblastic leukemia
CTR20260534Phase 3Active
- Sponsor
- Beijing Libang Biopharmaceutical Technology
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of BLB-101 in B cell acute lymphoblastic leukemia (B-ALL) (2 arms), sponsored by Beijing Libang Biopharmaceutical Technology. Primary endpoints: Steady-state concentration and day 1 AUC and CR/CRh during first two induction cycles. Started May 2026; status: active.
02
Drugs
BLB-101
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on CTR20260534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260534.